A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy

Trial Profile

A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 May 2016

At a glance

  • Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms MAGELLAN-1
  • Sponsors AbbVie
  • Most Recent Events

    • 15 Apr 2016 According to an Abbvie media release, in part-1 of this study 50 GT1 patients were randomized, part-2 of the study is underway in patients with compensated cirrhosis and in genotypes 4-6. Additional patients were enrolled in this study and received study drug at the higher doses of the combination, which will be used in Phase 3 clinical trials
    • 15 Apr 2016 According to an Abbvie media release, results based on an analysis of the intent-to-treat population from this trial presented at The International Liver Congress™ (ILC) 2016.
    • 15 Apr 2016 Results published in an Abbvie Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top